Results 161 to 170 of about 17,265,566 (310)
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Correction: Muscle quality correlates with hearing thresholds: a cross-sectional analysis. [PDF]
Front AgingJeon YJ, Lee JH, Kang BC, Kwon JK.
europepmc +1 more source
Welcome to the HAM-TMC Library, Vol.20 (1) July - September 2006 [PDF]
, 2006 Houston Academy of Medicine-Texas Medical Center Library
core +1 more source
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Visit the Winter Olympics Exhibit at the Library, Vol.4 (1) January - February 2006 [PDF]
, 2006 Houston Academy of Medicine-Texas Medical Center Library
core +1 more source
Tumor mutational burden as a determinant of metastatic dissemination patterns
Molecular Oncology, EarlyView.This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
Correction: Association between PFAS compounds in follicular fluid and POR and the intervention effect of Qizi Yusi Tang: a study based on targeted PFAS quantification analysis. [PDF]
Front Endocrinol (Lausanne)Li H +6 more
europepmc +1 more source
The Recovery Room, Vol.15 (1) January - February 2002 [PDF]
, 2002 Houston Academy of Medicine-Texas Medical Center Library
core +1 more source
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source